Nanoscope Therapeutics Announces Presentations at the 2023 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
DALLAS, May 11, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation at the 26th ASGCT Annual Meeting, taking place May 16-20, 2023 in Los Angeles, CA.
Details for the presentations are as follows:
Abstract Title: Optogenetic Therapy with MCO-010 for Vision Restoration in Patients with Severe Sight Loss Due to Retinitis Pigmentosa: The Phase 2b RESTORE Study
Dr. Liao will discuss Nanoscope's 52-week safety and efficacy outcomes from the Phase 2b RESTORE trial, the Company's most advanced clinical program. Efficacy and safety data from the RESTORE trial are consistent with those observed in the earlier Phase 1/2 trial, and thus provide compelling evidence on the benefit/risk profile of MCO-010 in retinitis pigmentosa.
About Nanoscope Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-presentations-at-the-2023-american-society-of-gene--cell-therapy-asgct-annual-meeting-301822118.html
SOURCE Nanoscope Therapeutics